ABSTRACT
OBJECTIVE: Cryopyrin-associated periodic syndromes (CAPS) result from gain-of-function mutations in the NLRP3 gene, which causes excessive release of interleukin-1ß (IL-1ß) and systemic inflammation. While pathogenetic NLRP3 variant phenotypes are well-characterized, low-penetrance NLRP3 variants represent a significant clinical challenge. The aims of this study were to determine the clinical phenotype, the in vitro biologic phenotype, and the effect of anti-IL-1 treatment in patients with low-penetrance NLRP3 variants. METHODS: A multicenter study of consecutive symptomatic patients with low-penetrance NLRP3 variants recruited from 7 centers between May 2012 and May 2013 was performed. The observed findings were transferred into a study database, from which they were extracted for analysis. Controls were patients with a known pathogenetic NLRP3 variant. Clinical presentation and CAPS markers of inflammation were captured. Functional assays of inflammasome activation, including caspase 1 activity, NF-κB release, cell death, and IL-1ß release, were performed. Treatment effects of IL-1 were determined. Comparisons between low-penetrance and pathogenetic NLRP3 variants were performed. RESULTS: The study included 45 patients, 21 of which were female (47%); 26 of the patients (58%) were children. NLRP3 low-penetrance variants identified in the patients were Q703K (n = 19), R488K (n = 6), and V198M (n = 20). In the controls, 28 had pathogenetic NLRP3 variants. Patients with low-penetrance NLRP3 variants had significantly more fever (76%) and gastrointestinal symptoms (73%); eye disease, hearing loss, and renal involvement were less common. Functional inflammasome testing identified an intermediate phenotype in low-penetrance NLRP3 variants as compared to wild-type and pathogenetic NLRP3 variants. All treated patients responded to IL-1 inhibition, with complete response documented in 50% of patients. CONCLUSION: Patients with low-penetrance NLRP3 variants display a distinct clinical phenotype and an intermediate biologic phenotype, including IL-1ß and non-IL-1ß-mediated inflammatory pathway activation.
Subject(s)
Cryopyrin-Associated Periodic Syndromes/genetics , Fever/genetics , Gastrointestinal Diseases/genetics , Inflammasomes/immunology , NLR Family, Pyrin Domain-Containing 3 Protein/genetics , Adolescent , Adult , Aged , Antirheumatic Agents/therapeutic use , Case-Control Studies , Caspase 1/metabolism , Cell Death/genetics , Cell Death/immunology , Child , Child, Preschool , Cryopyrin-Associated Periodic Syndromes/drug therapy , Cryopyrin-Associated Periodic Syndromes/immunology , Cryopyrin-Associated Periodic Syndromes/metabolism , Eye Diseases/drug therapy , Eye Diseases/genetics , Eye Diseases/immunology , Eye Diseases/metabolism , Female , Fever/drug therapy , Fever/immunology , Fever/metabolism , Gastrointestinal Diseases/drug therapy , Gastrointestinal Diseases/immunology , Gastrointestinal Diseases/metabolism , Genetic Variation , Hearing Loss/drug therapy , Hearing Loss/genetics , Hearing Loss/immunology , Hearing Loss/metabolism , Humans , Infant , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Interleukin-1beta/immunology , Kidney Diseases/drug therapy , Kidney Diseases/genetics , Kidney Diseases/immunology , Kidney Diseases/metabolism , Male , Middle Aged , NF-kappa B/metabolism , NLR Family, Pyrin Domain-Containing 3 Protein/immunology , Penetrance , Phenotype , Treatment Outcome , Young AdultABSTRACT
Familial Mediterranean fever (FMF) is the most inherited common autoinflammatory disease (AID) with mutations in the MEFV (MEditerraneanFeVer) gene.The Mor- and Pras-Score modified for children and C-reactive protein (CRP) were used to assess FMF disease severity in Germany. We evaluate the applicability of the 2 severity scores and the correlations between ethnic origin, phenotype, and genotype.Among 242 children (median 5 age at diagnosis), we detected 431 pyrin mutations and 22 different sequence variants, including one new mutation (p.Gly488Asp). The 5 most -frequent alterations were p.Met694Val (55.2%), p.Met680lle (11.8%), p.Val726Ala (10%), p.Glu148Gln (7.9%) and p.Met694IIe (2.3%). The prevailing ancestries of 223 cases were Turkish (82.5%) and Lebanese (8.1%). Homozygous p.Met694Val substitution (30.2%) was associated with a more severe disease activity by Mor-Score, as well as with a higher mean CRP (74 mg/l) compared to patients with other mutations. Indeed, Mor- and Pras-Score were inconsistent with each other. A typical distribution of mutations in different ethnic populations was obvious, but not statistically verifiable due to the low number of cases.The homozygous p.Met694Val substitution was associated with a more severe disease activity in our German cohort. The common severity scores were inconsistent in -children.
Subject(s)
Familial Mediterranean Fever/diagnosis , Familial Mediterranean Fever/genetics , Genotype , Phenotype , Adolescent , Alleles , Amino Acid Substitution/genetics , C-Reactive Protein/metabolism , Child , Child, Preschool , Cohort Studies , Cytoskeletal Proteins/genetics , DNA Mutational Analysis , Familial Mediterranean Fever/ethnology , Female , Gene Frequency/genetics , Germany , Homozygote , Humans , Infant , Lebanon/ethnology , Male , Methionine/genetics , Pyrin , Registries , Turkey/ethnology , Valine/geneticsABSTRACT
Rheumatic joint disease in childhood and adolescence is relatively rare. In the general population, 1 child with juvenile arthritis accounts for 100 adult patients with rheumatoid arthritis. At disease onset 50% of affected children are between 2 and 6 years of age. Symptoms are often subtle and pain is usually not the leading symptom. Early treatment of juvenile arthritis is essential in order to prevent long-term sequelae in affected children. Many children are introduced to a pediatric rheumatologist only with considerable delay. Therapy is based on NSAIDs, intra-articular steroid injections, and immunosuppressive drugs. In severe cases patients are treated with biologics. Physical and occupational therapy are important supportive measures in the treatment.
Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Juvenile/diagnosis , Arthritis, Juvenile/therapy , Physical Therapy Modalities , Adolescent , Child , Child, Preschool , Female , Humans , MaleABSTRACT
Rheumatic joint disease in childhood and adolescence is relatively rare. In the general population, 1 child with juvenile arthritis accounts for 100 adult patients with rheumatoid arthritis. At disease onset 50% of affected children are between 2 and 6 years of age. Symptoms are often subtle and pain is usually not the leading symptom. Early treatment of juvenile arthritis is essential in order to prevent long-term sequelae in affected children. Many children are introduced to a pediatric rheumatologist only with considerable delay. Therapy is based on NSAIDs, intra-articular steroid injections, and immunosuppressive drugs. In severe cases patients are treated with biologics. Physical and occupational therapy are important supportive measures in the treatment.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Antirheumatic Agents/administration & dosage , Physical Therapy Modalities , Rheumatic Fever/diagnosis , Rheumatic Fever/therapy , Steroids/administration & dosage , Adolescent , Child , Humans , Injections, Intra-ArticularABSTRACT
Mendelian susceptibility to poorly virulent mycobacteria such as bacillus Calmette-Guerin (BCG) and environmental nontuberculous mycobacteria is a clinically heterogeneous syndrome. The clinical features of affected children cover a continuous spectrum from disseminated lethal bacillus Calmette-Guerin infection to local recurrent nontuberculous mycobacterial infection. Different types of mutations in four genes (IFNGR1, IFNGR2, IL12B, IL12RB1) have revealed both allelic and nonallelic heterogeneity and result in eight different disorders whose common pathogenic pathway is impaired interferon gamma (IFNgamma) mediated immunity. The severity of the clinical phenotype depends on the genotype. Complete IL-12 p40 and IL-12 receptor beta1 deficiencies and partial IFNgamma receptor 1 (IFNgammaR1) and IFNgammaR2 deficiencies generally lead to curable infections at various ages, and antibiotics supplemented with IFNgamma if required are likely to be effective. Complete IFNgammaR1 and IFNgammaR2 deficiencies predispose to overwhelming infection in early childhood, which may respond to antibiotics but relapse when antibiotics are discontinued. Rapid discrimination between complete IFNgammaR1 and IFNgammaR2 deficiency and other defects, therefore, is an important diagnostic step for planning clinical management.